[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370565-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370565-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","changes-in-female-cancer-diagnostic-billing-rates-over-the-covid-19-period-in-the-ontario-health-insurance-plan","Changes in female cancer diagnostic billing rates over the COVID-19 period in the Ontario Health Insurance Plan","","Changes in female cancer diagnostic billing rates over 2020–2022 in Ontario were evaluated against pre-COVID-19 levels (2015–2019) using retrospective OHIP aggregated claims. Linear regression modeled counterfactual billing prevalence and incidence for each diagnostic billing code, and excess rates were computed as projected minus actual. Rates declined in 2020 for cervical, breast, uterine, and ovarian cancers, then increased in 2021 and further amplified in 2022, producing a cumulative positive excess across all female cancer types. Further research is required to characterize drivers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/changes-in-female-cancer-diagnostic-billing-rates-over-the-covid-19-period-in-the-ontario-health-insurance-plan/370565/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/changes-in-female-cancer-diagnostic-billing-rates-over-the-covid-19-period-in-the-ontario-health-insurance-plan/370565.png","ImageObject",300,407,{"name":42,"@type":43},"Riley West","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about COVID-19 and female cancers in Ontario?","Question",{"text":63,"@type":64},"It compares annual billing prevalence and incidence rates for female cancers during 2020–2022 against pre-COVID-19 levels from 2015–2019.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were excess billing rates calculated for 2020–2022?",{"text":68,"@type":64},"The study fit linear regression models to pre-COVID-19 (2015–2019) OHIP data for each billing code, extrapolated counterfactual values for 2020–2022, then computed excess as the difference between projected and actual rates for each year.",{"name":70,"@type":61,"acceptedAnswer":71},"What overall pattern of billing changes occurred across 2020–2022?",{"text":72,"@type":64},"Billing prevalence decreased in 2020 relative to projections, reversed to increases in 2021, and showed amplified excesses in 2022, leading to a largely positive net cumulative excess for all female cancer types studied.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370565,1791123955,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099523885074,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","TherapeuTic advances in  \nMedical Oncology Original Research  \n\n| Changes in female cancer diagnostic billing rates over the COVID-19 period in the Ontario Health Insurance Plan\u003Cbr>Deanna McLeod, Ilidio Martins, Anna V. Tinker, Amanda Selk, Christine Brezden-Masley, Nathalie LeVasseur and Alon D. Altman\u003Cbr>Abstract\u003Cbr>Background: The initial response to coronavirus disease 2019 (COVID-19) in Ontario included suspension of cancer screening programs and deferral of diagnostic procedures and many treatments. Although the short-term impact of these measures on female cancers is well documented, few studies have assessed the mid-to long-term impacts.\u003Cbr>Objectives: To compare annual billing prevalence and incidence rates of female cancers during the COVID-19 period (2020–2022) to pre-COVID-19 levels (2015–2019) .\u003Cbr>Design: Retrospective analysis of aggregated claims data for female cancer diagnostic codes from the Ontario Health Insurance Plan (OHIP) .\u003Cbr>Methods: Linear regression analysis was used to fit pre-COVID-19 (2015–2019) data for each OHIP billing code and extrapolate counterfactual values for the years of 2020–2022. Excess billing rates were calculated as the difference between projected and actual rates for\u003Cbr>each year.\u003Cbr>Results: In 2020, OHIP billing prevalence rates for cervical, breast, uterine, and ovarian cancers decreased relative to projected values for that year by −50 . 7/100k, −13 . 9/100k,−3 . 5/100k, and −3 .8/100k, respectively. The reverse was observed in 2021 with rate increases of 47 .8/100k, 59. 1/100k, 2. 5/100k, and 3. 7/100k, respectively. In 2022, the excesses were further amplified, especially for cervical and breast cancers (111 . 2/100k and 78. 67/100k, respectively) . The net excess patient billing rate for 2020–2022 was largely positive for all female cancer types (108 .3/100k, 123. 7/100k, 5. 2/100k, and 1.8/100k, respectively) . Analysis of billing incidence rates showed similar trends.\u003Cbr>Conclusion: The expected female cancer billing rate decreases in 2020 were followed by large increases in 2021 and 2022, resulting in a cumulative excess during the COVID-19 period. Further research is required to assess the nature of these changes.\u003Cbr>Keywords: breast cancer, COVID-19, diagnostic claims, gynecological cancers, public health measures\u003Cbr>Received: 17 December 2024; revised manuscript accepted: 18 April 2025. |  | TherAdv Med Oncol 2025, Vol. 17: 1–22\u003Cbr>DOI: 10. 1177/ 17588359251339919 © The Author(s), 2025.\u003Cbr>Article reuse guidelines: [sagepub.com/journals](sagepub.com/journals)permissions\u003Cbr>Correspondence to:\u003Cbr>Anna V. Tinker\u003Cbr>BC Cancer Agency, BC Cancer—Vancouver Centre, University of British Columbia, 600 West 10th Avenue, 4th Floor, Vancouver, BC V5Z 4E6, Canada\u003Cbr>atinker@bccancer.bc.ca\u003Cbr>Deanna McLeod Ilidio Martins\u003Cbr>Kaleidoscope Strategic Inc. , Toronto, ON, Canada\u003Cbr>Amanda Selk\u003Cbr>Women’s College Hospital, Toronto, ON, Canada\u003Cbr>Christine Brezden-Masley\u003Cbr>Sinai Health System—Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada\u003Cbr>Nathalie LeVasseur\u003Cbr>BC Cancer—Vancouver Centre, University of British Columbia, Vancouver, BC, Canada\u003Cbr>Alon D. Altman\u003Cbr>CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada |\n| --- | --- | --- |\n| Introduction\u003Cbr>The World Health Organization declared the coronavirus disease 2019 (COVID-19) a Public Health Emergency of International Concern on January 30, 2020, and recommendations were issued to prevent disease transmission.1 In the Canadian province of Ontario, a State of Emergency (SOE) was declared on March 17, | 2020 leading to the implementation of public health measures such as social distancing, quarantine and isolation, and changes to in-person public health services and workforce as well as widespread closures of businesses and schools.2 As the first provincial SOE period expired on July 24, 2020, many public health measures were canceled or eased, with others remaining in effect |  |\n\n[journals.sagepub.c","cbCaiqR1cDmZ9zZd","https://ap.wps.com/l/cbCaiqR1cDmZ9zZd","pdf",1443534,22,"English","# Abstract\n## Background and Objectives\n## Design and Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What question does the study address about COVID-19 and female cancers in Ontario?\",\"answer\":\"It compares annual billing prevalence and incidence rates for female cancers during 2020–2022 against pre-COVID-19 levels from 2015–2019.\"},{\"question\":\"How were excess billing rates calculated for 2020–2022?\",\"answer\":\"The study fit linear regression models to pre-COVID-19 (2015–2019) OHIP data for each billing code, extrapolated counterfactual values for 2020–2022, then computed excess as the difference between projected and actual rates for each year.\"},{\"question\":\"What overall pattern of billing changes occurred across 2020–2022?\",\"answer\":\"Billing prevalence decreased in 2020 relative to projections, reversed to increases in 2021, and showed amplified excesses in 2022, leading to a largely positive net cumulative excess for all female cancer types studied.\"}]","Changes in female cancer diagnostic billing rates over the COVID-19 period in the Ontario Health Insurance Plan | PDF",1790189187,55,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c263756c91a057128c48def2d5bd13e.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2218e5a9f5b4f53f48b98578d4aa4e53.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f2650212ab8c15f15deb83b56e536c8b.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c3cae2b59737afc0684cf01238344432.webp",980,1306]